CA1340853C - Purification of recombinant interleukin-2 - Google Patents
Purification of recombinant interleukin-2Info
- Publication number
- CA1340853C CA1340853C CA000470498A CA470498A CA1340853C CA 1340853 C CA1340853 C CA 1340853C CA 000470498 A CA000470498 A CA 000470498A CA 470498 A CA470498 A CA 470498A CA 1340853 C CA1340853 C CA 1340853C
- Authority
- CA
- Canada
- Prior art keywords
- cell membrane
- membrane components
- solution
- detergent
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 86
- 102000000588 Interleukin-2 Human genes 0.000 title claims description 80
- 238000000746 purification Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 34
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 23
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 17
- 244000005700 microbiome Species 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 10
- 239000003599 detergent Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000001042 affinity chromatography Methods 0.000 claims description 6
- 239000013592 cell lysate Substances 0.000 claims description 6
- 102000055277 human IL2 Human genes 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 229960004198 guanidine Drugs 0.000 claims description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 2
- 238000011097 chromatography purification Methods 0.000 claims 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006166 lysate Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 30
- 241000588724 Escherichia coli Species 0.000 description 26
- 239000000243 solution Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 239000002299 complementary DNA Substances 0.000 description 19
- 210000004379 membrane Anatomy 0.000 description 19
- 239000012528 membrane Substances 0.000 description 19
- 239000013598 vector Substances 0.000 description 18
- 238000010276 construction Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- RTLULCVBFCRQKI-UHFFFAOYSA-N 1-amino-4-[3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=1)=CC=C(S(O)(=O)=O)C=1NC1=NC(Cl)=NC(Cl)=N1 RTLULCVBFCRQKI-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 239000012630 HPLC buffer Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000006167 equilibration buffer Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004952 protein activity Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LMWMTSCFTPQVCJ-UHFFFAOYSA-N 2-methylphenol;phenol Chemical compound OC1=CC=CC=C1.CC1=CC=CC=C1O LMWMTSCFTPQVCJ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MGOGKPMIZGEGOZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanamide Chemical compound OC[C@H](N)C(N)=O MGOGKPMIZGEGOZ-REOHCLBHSA-N 0.000 description 1
- MJQHZNBUODTQTK-UHFFFAOYSA-N 2-[[3-[2-[(3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(CO)OC1OC1C2OCC1OC(OC1C(C(OC3C4OCC3OC(O)C4O)OC(CO)C1O)O)C2O MJQHZNBUODTQTK-UHFFFAOYSA-N 0.000 description 1
- 102100028247 Abl interactor 1 Human genes 0.000 description 1
- 108050004693 Abl interactor 1 Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 101100114416 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-10 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000409 membrane extraction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- -1 phenylmethylsulfonyl Chemical group 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Method for the preparation of substantially homogeneous recombinant mature human IL-2 comprising separating the cell membrane components from a lysate of transformed microorganisms which have expressed and accumulated IL-2, extracting IL-2 from the cell membrane components and purifying chromatographyically the extract.
Description
Human interleukin-2 (I1-2), formerly called T-cell growth factor, is a soluble protein which can be produced from T-cells activated with a lectin or an antigen and which is capable of modulating lymphocyte reactivity and promoting the long-term in vitro culture of antigen-specific effector T-lymphocytes. IL-2 is also known to enhance thymocyte mito-genesis and to induce cytotoxic T-lymphocyte reactivity.
Accordingly, this lymphocyte regulatory substance is useful in potentiating humoral and cellular immune responses and in restoring immune deficient state to a normal humoral and cellular immune state. These identified immunological acti-vities of IL-2 indicate that IL-2 is useful for medical immunotherapy against immunological disorders including neo-plastic diseases, bacterial or viral infections, immure deficient diseases, autoimmune diseases etc. (Papermaster, B. et al., Adv. Immunopharm., 507, [1980]). Recently, a review article in the Journal of The American Medical Asso-ciation, Vol. 249, No. 2 at pages 166-171 (January 14, 1983) discusses the clinical applications of various lymphokines including particularly human IL-2.
Human IL-2 derived from induced human malignant cells has recently been purified to homogeneity using multiple high performancee liquid chromatography (HPLC) steps. The resulting homogeneous human IL-2 demonstrated a specific activity of about 1.4 x 109 units/mg (see e.g. European patent application No. 83.109202.8, publication No. 106 179).
Taniguchi et al. reported on the cloning and sequencing of the IL-2 gene and expression of the immature form of human Interleukin-2 at the Third Annual Recombinant DNA
congress in Philadelphia, Pennsylvania on February 9, 1983 ~~4.~8~~
Accordingly, this lymphocyte regulatory substance is useful in potentiating humoral and cellular immune responses and in restoring immune deficient state to a normal humoral and cellular immune state. These identified immunological acti-vities of IL-2 indicate that IL-2 is useful for medical immunotherapy against immunological disorders including neo-plastic diseases, bacterial or viral infections, immure deficient diseases, autoimmune diseases etc. (Papermaster, B. et al., Adv. Immunopharm., 507, [1980]). Recently, a review article in the Journal of The American Medical Asso-ciation, Vol. 249, No. 2 at pages 166-171 (January 14, 1983) discusses the clinical applications of various lymphokines including particularly human IL-2.
Human IL-2 derived from induced human malignant cells has recently been purified to homogeneity using multiple high performancee liquid chromatography (HPLC) steps. The resulting homogeneous human IL-2 demonstrated a specific activity of about 1.4 x 109 units/mg (see e.g. European patent application No. 83.109202.8, publication No. 106 179).
Taniguchi et al. reported on the cloning and sequencing of the IL-2 gene and expression of the immature form of human Interleukin-2 at the Third Annual Recombinant DNA
congress in Philadelphia, Pennsylvania on February 9, 1983 ~~4.~8~~
(Nature, 302, 305-310 [1983]). The cDNA from which the amino acid sequence of the IL-2 protein was derived was prepared from mRtJA obtained from Jurkat cells induced with Concanava-lin A. The full length cDNA clone is 800 base pairs long and codes for a protsin of 153 amino acids. See also European patent application, publication No. 91539.
Other groups have also reported the cloning and sequen-cing of the IL-2 gene. See Devos et al., ~~Molecular Cloning of Human Interleukin-2 cDNA and Its Expressior_ in E. coli~~, Nucleic Acids Research, 11, 4307-4323 (1983). See also Euro-pean patent application, publication No. 118 977.
Although these references describe the expression of IL-2 in transformed host cells, especially in E. coli, no purification procedures are disclosed which would permit one skilled in the art to obtain mature recombinant human IL-2 in a homogeneous or'substantially pure form.
The present invention relates to a process for the puri-fication of recombinant IL-2 especially of recombinant mature human IL-2. It provides a method for the purification of recombinant mature human IL-2 to homogeneity which over-comes the limitations of prior art purification methods.
This method comprises (a) cultivating a transformed organism containing a DNA
sequence which codes for mature human IL-2;
(b) causing a culture of the transformed organism of step (a) to express and accumulate mature human IL-2:
(c) lysing the culture of transformed organisms of step (b) to form a cell lysate mixture;
(d) separating the cell membrane components from the cell lysate mixture of step (c);
(e) ~,aasring the isolated cell membrane components with an extraction solution to yield a wash solution containing IL-2 ; and (f) chromatographically purifying the wash solution of step (e) to yield a substantially pure or homogenous recombinant human IL-2.
Brief Description of the Drawings Fig. 1 represents the DNA nucleotide sequence of pIL2-2B
and the corresponding amino acid sequence of mature human interleukin-2 (arrow represents amino terminus of mature IL-2 protein).
Fig. 2 graphically illustrates the construction of pRC2 from pBR322.
Fig. 3 graphically illustrates the construction of pRC23 containing a PL promoter.
Fig. 4 shows the construction of the structural gene for expression of Ser-IL-2.
Fig. 5 graphically illustrates the construction of a mature IL-2 expression vector without a promoter system (pRC
201/IL-2).
Fig. 6 graphically illustrates the construction of the mature IL-2 expression vector including a PL promoter system (pRC 233/IL2).
The procedure of the present invention relies on the surprising finding that the IL-2 protein expressed by a microbe tends to associate with the membrane fractions of the host microbe, principally the inner membrane of the microbe (the membrane being a lipid bi-layer often associa-ted with hydrophobic proteins). Therefore, separation of these membranes during the process of recovering IL-2 from the transformed microorganisms ensures high yield and purity levels of IL-2 at the end of the whole purification proce-dure.
While different known methods of cell lysis can be used in the process of the present invention, such as enzymatic or chemical lysis, lysis by sonification is the preferred method. The inner and outer cell membranes are then separa-ted from the other cellular components by known methods such as centrifugation.
Once the cell membranes are separated from the lysate mixture, they are washed with an extraction solution, pre-ferably salt and detergent solutions to yield a solution comprising at least about 50% IL-2. In a preferred embodi-ment, the cell membranes are washed in four separate steps with the salt and detergent solutions. The first step pre-ferably comprises washing the cell membranes with a salt solution, preferably 1M NaCl. In the second step the cell membrane fraction is washed with a detergent solution, pre-ferably 1% Triton X-100. In the third step the cell membrane fraction is washed with another salt solution, preferably 1.75M to 2M guanidine-HCl. The final wash is also with a salt solution, preferable about 4M to 7M guanidine-HC1. The wash solution which results from the fourth and final wash comprises at least about 50% IL-2.
The final IL-2 wash solution is then further purified by chromatography, preferably by reverse phase high performance liquid chromatography (HPLC). The HPLC step yields active IL-2 in a substantially 100% pure or homogeneous form. It is also forseeable that antibody affinity chromatography columns, utilizing polyclonal or monoclonal antibodies to IL-2, could be used as an alternative to HPLC. Other chroma-tographic procedures can also be utilized such as dye-affi-nity columns (e.g., Procion red agarose - as described in European Patent Application No. 83103582.9 published under No. 92163 on October 26, 1983) or sephacryl*5200 columns. In another preferred embodiment of this invention the chromatc-* trade mark.
_ 5 _ graphy comprises multiple steps, i.e. HPLC followed by a dye-affinity chromatography step.
In accordance with this invention the aforementioned purified IL-2 can be used for similar purposes as the other known immunomodulator compounds, e.g. as a means for trea-ting immunosuppressive conditions. It may be administered in pharmaceutically acceptable oral, injectable or topical com-position and modes. Dosage and dose rate may parallel that currently being used in clinical applications of known immunomodulator compounds, typically about 1-200 x106 units daily. These pharmaceutical compositions of the inven-tion contain said IL-2 in association with a compatible pharmaceutically acceptable carrier material. Any conventio-nal carrier material can be utilized. The carrier material can be an organic or inorganic inert carrier material sui-table for enteral, percutaneous or parenteral administra-tion. Suitable carriers include water, gelatin, gum arabic, lactose. starch, magnesium stearate, talc, vegetable oils, polyalkylene-glycols, especially polyethylene-glycols, petroleum jelly and the like. Furthermore, the pharmaceu-tical preparations may contain other pharmaceutically active agents. Additional additives such as flavoring agents, preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding.
The pharmaceutical preparations can be made up in any conventional form including: a) a solid form for oral administration such as tablets, capsules, pills, powders, granules, and the like; b) a liquid form for oral adminis-tration such as solutions, syrups, suspensions, elixirs and the like; c) preparations for parenteral administration such as sterile solutions, suspensions or emulsions; and d) pre-parations for topical administrations such as solutions, suspensions, ointments, creams, gels, micronized powders, aerosols and the like. The pharmaceutical preparations may be sterilized and/or may contain adjuvants such as preserva-tives, stabilizers, wetting agents, emulsifiers, salts for varying the osmotic pressure and/or buffers.
Parenteral dosage forms may be infusions or injectable solutions which can be injected intravenously or intramuscu-larly. The preparations can also contain other medicinally active substances. Additional additives such as preservati-ves, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of phar-l0 maceutical compounding.
The construction of IL-2 expression vectors and of transformants capable of expressing IL-2 is described in more detail below.
The amino acid sequence of the mature IL-2 protein is given in Figure 1. The~protein may be expressed in its mature form with a methionine at the amino terminus of the protein if the gene initiation codon is ATG. The methionine may or may not be removed by the host cell after expression.
The expression vectors used in this invention are deri-vatives of pBR322 containing the PL promoter isolated from bacteriophage lambda DNA. PL was the promoter of choice since it is a very strong promoter that can be efficiently and conveniently controlled by the lambda cI repressor, the gene for which may be located on the microorganism s chromo-some, a compatible vector or the same vector as that con-taining the PL promoter. The gene encoding the repressor carries a mutation, cIts, which renders tre repressor tempe-rature-sensitive. A vector which may be used with this invention and which contains the cI mutation is pRK248cIts, which is known in the art and is described by Kahn et al., P4ethods in Enzymology, 68, 268 (1979). At 30°C the repressor functions normally, and from about 37°C to about 42°C it is inactivated. Thus, the Pr promoter is repressed (turned--cff) at 30°C and derepressed (turned-on) at 42°C. The abi-1~~08~3 _ 7 _ ~, lity to control the PL promoter allows one to grow the culture at about 30°C to about 36°C without expressing the gene product and at an optimum time, shift the temperature from about 30°C to about 42°C to produce the desired mature human IL-2 product.
The preferred vector used in the present invention also contains an EcoRI restriction site distal (downstream in 3' direction) from the SD sequence. The following description serves to illustrate the preparation of a preferred vector, pRC23, into which the IL-2 gene is then introduced. However, other vectors may also be used.
In accordance with the procedure outlined in Figures 2 and 3 20 micrograms of pBR322 were digested with EcoRI and then used in two different reactions: 1) treatment with S1 nuclease to remove the 5' overhang, and 2) treatment with the Klenow fragment of DNA polymerase I to fill-in the ter-mini. Both reactions were terminated by phenol extraction followed by ethanol precipitation. DNA from each reaction was ligated to a synthetic BglII linker, digested with BglII
and PstI, and subjected to gel electrophoresis in 1% aga-rose. The 3600 by (base pairs) and 760 by fragments from both reactions were recovered from the gel. For the con-struction of pRC2, the 3600 by fragment from the Klenow reaction was ligated to the 760 by fragment from the S1 reaction. E. coli RR1 was transformed with the ligation mixture and transformants were selected on media containing 50 ug/ml ampicillin. Transformants containing the expected plasmid construction, i.e. a plasmid containing a BglII
restriction site in proximity of the EcoRl restriction site, were identified by restriction analysis of the isolated plasmid DNA. pRC23 was constructed by ligating synthetic oligonucleotides comprising a "consensus" or computer gene-rated ribosome-binding site (RBS), [Scherer et al. Nucleic Acids Research, 8, 3895 (1980)] to a 250 by Bgl II - Hae III
fragment containing the lambda. PL promoter, and inserting -a-~3~~~~3 the ligation product into pRC2.
In order to isolate the 250 by DNA fragment containing the lambda PL promoter, 1 microgram of a 450 by Bgl II -Hpa I DNA fragment (from by #35260 to 35710 of the lambda phage DNA sequence) was digested with Hae III and the pro-ducts were isolated by preparative gel electrophoresis in 5%
polyacrylamide. About 200 ng of the 250 by Bgl II - Hae III
fragment was ligated to 60 pmoles each of the synthetic oligonucleotides shown in Figure 3 which comprise most of the ~~consensus~~ RBS sequences generated by computer analysis as described by Scherer et al. The ligated molecules were digested with Bgl II and EcoRl (to eliminate oligomers) and purified by gel electrophoresis. The ligated products were then inserted into pRC2 which also had been digested with Bgl II and EcoRI. Transformation of E. coli strain RR1(pRK248cIts) was performed using standard methods and transformants were seclected on media containing ampicillin (50 ug/ml) at 30°C. 50 transformants were obtained, DNA
was isolated from 8 of those and analyzed by digesting with Hinc II. 6 of the 8 showed the expected restriction pattern and Maxam-Gilbert nucleotide sequence analysis of one of these confirmed the expected construction (designated pRC23).
Construction of a alasmidic expression vector containinu DN_A
coding for mature human IL-2 (1) Isolation of mRNA coding for human IL-2 mRNA was isolated from H33HJ-JAI cells (ATCC No.
CRL-8163, deposited August 26, 1982), a clone of Jurkat cell line FHCRC, after induction with PHA and PMA.
12,000 ml of H33HJ-JAI clone cell cultures (106 cells/ml) were grown in RPMI 1640 tissue culture medium supplemented with 10% Fetal Bovine Serum, 50 U/ml peni-cillin, 50 ug/ml streptomycin, 50 ug/ml gentamycin, and 300 ug/ml fresh L-glutamine. These cells were collected by centrifugation and resuspended in 6 1 of 13~0~~3 _ g _ the above detailed medium, lacking serum, but further supplemented with 1% PHA and 10 ng/ml PMA. Cells were dispended in 6 1 aliquots to sterile glass roller bottles and placed on a roller mill (10 rpm at 37°C).
Eight hours later, cells were collected by centrifuga-tion and mRNA was extracted using a standard phenol chloroform extraction procedure. Following phenol chloroform extraction, ethanol precipitated RNA was pelleted by high speed centrifugation, and resuspended in a 0.5M salt solution. Poly A-tailed mRNA contained in the total RNA population was collected by passage of this material over an oligo(dT)cellulose column. Ethanol precipitated mRNA was resuspended in water to a concen-tration of 500 ug/ml. 30 ng of RNA was then microin-jected into Xenopus oocytes. After 24 hours of incuba-tion in sterile Barth~s solution, 4 eggs were trans-ferred into a sterile 1.5 ml Eppendorf centrifuge tube and fed with 540-1500 microliters of fresh sterile Barth~s solution. 48 hours later, 200 microliters of egg conditioned medium was harvested and assayed for IL-Z
activity using a standard CTLL Cell 3H-Tdr incorpora-tion assay (Gillis et al., J. Immunoi. 120, 2027 [1978]). mRNA preparations which when translated by oocytes gave rise to significant IL-2 activity, were pooled, sized by standard sucrose density gradient centrifugation techniques and ethanol precipitated for cDNA library construction.
(2) cDNA Synthesis 3.5 ug of purified mRNA (approximately 10S on sucrose gradients) were used to synthesize double-stranded complementary DNA (ds cDNA) by the following method (Gubler and Hoffmann, Gene 25, 263-269 [1983]).
~3~-0853 (a) First strand cDNA synthesis:
The mRNA was suspended in 17.5 ml containing 50 mM
Tris-HC1, pH 8.3, 10 mM MgCl2, 10 mM DTT, 4 mM
Na-pyrophosphate, 1.25 mM dATP, 1.25 mM dGTP, 1.25 mM dTTP, 0.5 mM dCTP, 100 ug/ml of oligo(dT)12-18' and 10 Ci of 32P-dCTP (Amersham 3000 Ci/mMole). After incubation for 5 min. at 43°C, 3x00 units AMV reverse transcriptase/ml (Life Sciences, Inc.) was added and the mixture incubated for 30 min. at 43°C. The reaction was stopped by the addition of EDTA to 20 mM, extracted with phenol-cresol, and concentrated by ethanol precipi-tation. The yield of the first strand synthesis, as assayed by TCA-insoluble radioactivity, was calcu-lated to be 58.6 ng (1.7%).
(b) Second strand synthesis: , The cDNA-mRNA hybrid was resuspended in 5.8 micro-liters H20. To this solution, 7.7 microliters of the second strand synthesis mix was added to give a solution containing 20 mM Tris-HC1, pH 7.5, 5 mM
MgCl2, 10 mM (NH4)2504, 100 mM KC1, 0.15 nM
beta-NAD, 50 ug/ml BSA, 40 mM dNTPs, 8.5 units/ml of E. coli RNase H (Bethesda Research Labs), 230 Units/ml DNA polymerase I (Boehringer Mannheim), 10 units/ml E.coli DNA ligase (New England Biolabs).
The mixture was incubated for 60 min. at 12°C, then for 60 min. at 22°C. The reaction was stopped by addition of EDTA to 20 mM, and extracted with phenol-cresol. The cDNA was separated from free nucleotides by passage over a Sephadex G-50 fine column in 10 mM TEAB. The yield from this reaction was 107 ng of dscDNA (91%).
(~) Annealing and transformation 64 ng of dscDNA were tailed by addition of dGTP
using standard methods. The vector was prepared by digestion of pBR322 DNA with EcoRV (New England-Biolabs) and tailing with dCTP. 100 ng of tailed BR322 DNA and 1.25 ng of tailed cDNA inserts (ratio - 80:1) were annealed in 250 ul of O.O1M
Tris, pH 7.5, 1 mM EDTA, 0.15 M NaCl for 90 min. at 58°C, and transformed into competent E.coli RRI
cells. Transformed cells were plated on LB plates containing 100 ug/ml ampicillin (Bristol Labs), and incubated at 3?°C for 12 hours. A total of 3,200 colonies were generated for the IL-2 cDNA
library.
(3) Screenincr of cDNA library for.IL-2 gene seauences To detect full-length cDNA copies of the IL-2 gene, a synthetic deoxy-oligonucleotide probe was used which corresponds to nucleotides 45-65 of the human IL-2 cDNA
sequence published by Taniguchi~ et al. (Nature 302, 305-310 [1983]). This probe [ACAATGTACAGGATGCAACTC] was synthesized by the solid-phase phosphodiester method, purified by HPLC, and labeled by using 32P-ATP (ICN
Pharmaceuticals, 7000 Ci/mM) and polynucleotide kinase (New England Biolabs). Colonies representing the cDNA
library were transferred to nitrocellulose filters by the method of Grunstein and Hogness (Methods in Enzymo-logy 68, 379 [1979]). After hybridization at 30°C for 16 hours, filteres were washed in 4xSSC at 45°C for 45 minutes, dried, and autoradiographed. A single posi-tive colony was detected and found to contain the entire IL-2 coding sequence. This colony, designated pIL2-2B, was used to prepare DNA for nucleotide sequence analysis and for expression in E.coli. Nucleotide sequence analy-sis showed it to be identical to that of the sequence published by Taniguchi et al. with two differences:
pIL2-2B contains an insert which begins at nucleotide 17, as designated in the Taniguchi sequence, and has a substation of a G at position 503.
.. ~~~OS~3 (4) Construction of the E.coli plasmidic vector containin DNA coding for Ser-IL-2.
An E.coli expression vector for IL-2 was constructed from three segments (see Fig. 4): (1) the vector pRC23, with the lambda PL promoter, (2) a synthetic adapter molecule, and (3) a Hgi AI - Aha III fragment isolated from the IL-2 cDNA. The vector DNA was prepared by digestion of 50 ng of pRC23 DNA with EcoRI and EcoRV, followed by phenol extraction and ethanol precipitation.
l0 The synthetic adagter molecule was obtained by annealing two complementary synthetic deoxy-oligonucleotide sequences, A and B:
(A) 5' AATTCAATTATGAGTGCA 3' (B) 3' GTTAATACTC 5' This double-stranded adapter can anneal to an EcoRI site at its 5' end and to a HgiAI site at its 3' end. The cDNA insert was prepared by digestion of pIL2-2B DNA
with the restriction enzyme BamHl (Bethesda Research Labs), which releases the 1 kilobase IL-2 insert from this clone. The BamHl fragment was gel-purified and further digested with HgiAI (New England Biolabs) and Aha III (New England Biolabs), then phenol-extracted and ethanol precipitated. HgiAI cuts between the alanine and proline codons at the beginning of the sequence coding for mature IL-2. The cloning strategy for expression uses the EcoRI site adjacent to the PL promoter in the pRC23 vector. The synthetic adapter molecule can join this EcoRI site in the vector to the HgiAI site at the start of the cDNA IL-2 sequence. The adapter was desig-ned to create the methionine codon for translation ini-tation. Codons for serine and for alanine, the first amino acid of mature IL-2, are created when the adapter and the cDNA are ligated at the HgiAI site. The cDNA is joined to pRC23 via blunt-end ligation of the AhaIII
site to the EcoRV site in the vector DNA.
M
- i3 -Ligation of the three segments was performed in a volume of 10 y.l which contained 0.05 pM each of the vector, synthetic adapter and cDNA insert DNAs, 65 mM Tris, pH
7.6, 10 mM MgCl2, 0.5 mM ATP, and 15 mM beta-mercapto-ethanol. The ligation mixture was heated at 65°C for 5 minutes, cooled to 4°C before addition of 200 Units of T4 DNA ligase (New England Biolabs), then incubated at 4°C for 16 hours. The T4 DNA ligase was inactivated by heating at 65°C for 5 minutes. Then the ligated DNAs were digested with EcoRV to remove any undigested vector DNA. The mixture was then used for transformation of E.coli strain RRI (pRK248cIts), and these cells were grown at 30°C for 15 hcurs.
The colonies were transferred to nitrocellulose filters as described previously, baked, and hybridized with a radioactive probe of 32P-labeled synthetic adapter molecule A. One positive colony, designated pRC23/IL-2, #4-1, was chosen for analysis. This clone was found to synthesize more than 200,000 units/ml of IL-2 when the PL promoter was induced to express at 42°C. The IL-2 activity was detected by bioassay on CTLL cells, an indicator cell line for IL-2 (as described in Gillis et al. J. Immunol. 120, 2027 [1978]).
(5) Construction of an E.coli ex ression vector for urodu-cing mature IL-2 (with alanine as the first amino acid at the amino terminus) To express mature IL-2 in E.coli, the following strategy (illustrated in Fig. 5) was followed. A HgiAI restric-tion endonuclease site is located at the Ser-Ala junc-tion, the cleavage site for the removal of the signal peptide of IL-2 (Robb et al., PNAS, 80, 5990-5994 [1983]). Following digestion with HgiAI, the termini were made blunt-ended by treating with T4 DNA poly-merase. The resulting molecules were then blunt-end ligated to a 108 by BglII-Hae III fragment isolated from phage lambda DNA, digested with BglII and XbaI and inserted between BglII and RbaI sites in the vector pRC23/IL-2, #4-1. This intermediate cloning step was included to ensure that the T4 DNA polymerase treatment occurred as expected, which was confirmed by the crea-tion of a new StuI site from the joining of the HaeIII
terminus to the blunt-ended HgIAI terminus. Redigesting with StuI conveniently regenerates at this site the blunt end beginning with the CCT proline codon. The intermediate plasmid construction was designated pRC201/I1-2. Two synthetic deoxyoligonucleotides were designed which incorporate an ATG-translational initia-tion codon, restore the alanine codon, and create an EcoRI terminus. These oligomers were ligated to the EcoRI terminus of the expression vector pRC23, digested with PstI, and the resulting 1025 by fragment was gel purified. The 1025 by (PstI to blunt-end) fragment was inserted between the PstI site and the newly created StuI site in pRC201/IL-2. Transformants containing the expected construction were identified by restriction analysis of the isolated plasmid DNA. The confirmed plasmid construction was designated pRC233/I1-2 (see Fig. 6).
Preferred host organisms for transformation by a vector containing the gene for IL-2 in connection with the present invention include bacteria such as strains of E.coli; bacillaceae, such as Bacillus substillis and the like. Yeasts form a further preferred group of microorganisms for transformation.
A specifically preferred microorganism employed as the recipient in the transformation procedures is Esche-richia coli K-12 strain 294 as described in British patent Publication No. 2055382A, deposited with the American Type Culture Collection, ATCC Accession No.
31446, on October 28, 1978. However, also other known 13~.0~~3 E.coli strains such as E.coli RR1, ATCC Accession No.
31343, or other microorganisms many of which are deposi-ted and available from recognized microorganism deposi-tory institutions, such as the American Type Culture Collection can be used as host organisms. In the prac-tice of this invention overnight cultures of the trans-formed E.coli are grown in LB broth at 30°C. One liter of the overnight culture is preferably diluted to 10 liters with minimal M-9 medium containing casamino acids. At logarithmic growth, the culture is shifted from 30°C to 42°C to induce IL-2 production. Following incubation at 42°C for 2-3 hours, the bacteria are harvested by centrifugation. All fermentations and procedures were performed in accordance with recombinant DNA guidelines of the National Institutes of Health. The purification steps are described in detail in the follo- -wing Examples.
Example 1 One gram of IL-2 (having serine at the NH2 terminus) producing transformed E.coli cells were suspended in 30 mM
Tris-HC1, pH 8.0, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride and lysed by sonification. The lysis mixture was centrifuged at 14,000 x g for 15 minutes. The membrane portion of the centrifuged lysate was then removed and iso-lated from the other components of the lysate. The membrane component was then subjected to the four washing or IL-2 extraction steps shown below in Table 1. Each wash solution was used in an amount of at least 5 ml/gram of cells. The bulk of the IL-2 activity was extracted in the final wash as detailed in Table 1. The final resultant wash solution which contained the bulk of the IL-2 activity and which was at least about 50% pure as judged by SDS-PAGE, was then subjec-ted to reverse phase HPLC (RP-C8). There was a 40-60% reco-very of substantially 100% pure IL-2 (with serine at the NH2 terminus). The IL-2 activity was found to be at least <",, , *Trademark -16 - ~3~0~~~
1 x loa u/mg.
Table 1 Extraction of IL-2 from E.coli membrans Total Total IL-2 Specific Protein Activity Activity Extraction (mcr) units u/m 1M NaCl wash 0.4 mg 0.03 x 106 0.1 x 106 1% Triton wash 2 mg 0.75 x 106 0.4 x 106 1.75 guanidine-HC1 wash 1 mg 1.5 x 106 1.5 x 106 7M guanidine-HC1 wash 4.7 mg 250 x 106 53 x 106 (99%) 252.3 x 106 Example 2 This example serves to demonstrate that IL-2 tends to become associated with the membrane components of the trans-formed E.coli host cells.
In order to demonstrate this, one gram of serine-NH2 terminus IL-2 producing transformed E.coli cells were sus-pended in 10 ml of 20% sucrose, 30 mM Tris-HC1, pH 8.0, and lysed using lysozyme-EDTA to separate proteins which are localiced in the periplasmic space. The remainder of the lysed mixture was then subjected to sonification. The mem-brane portion (inner and outer membranes) was then separated from the other cellular components by sucrose gradient cen-trifugation with which the inner and outer membranes were also separated. Table 2 shows that the majority of IL-2 activity was located in the inner cellular membrane.
_ 17 - ~3~O8~J
Table 2 Localization of IL-2 in E.coli cells Total Total IL-2 Recovery of Protein Activity IL-2 Fraction (mct) (units) [%~
Soluble Fraction 37 mg 2 x 106 0.3 Periplasmic Fraction 2 mg 10 x 106 1.5 Outer Membrane 6 mg 8 x 106 1.2 Inner Membrane 15 mg 6.6 x 108 97 Example 3 One gram of mature IL-2 producing transformed E.coli cells was suspended in 30 mM Tris-HC1, pH 8, 5 mM EDTA, 1 mM
phenylmethylsulfonyl'fluoride and lysed by sonification. The lysis mixture was centrifuged at to 14,000 x g for 15 minu-tes. The membrane portion of the centrifuged lysate was iso-lated from the other components of the lysate. The membrane portion was then subjected to the four washing or IL-2 extraction steps shown below in Table 3. Each wash solution was used in an amount of at least 5 ml per each gram of cells. The bulk of the IL-2 activity was finally extracted in the final wash as detailed in Table 3. The final resul-tant wash solution which contained the bulk of the IL-2 activity and which was at least 50% pure as judged by SDS--PAGE, was then subjected to reverse phase high performance liquid chromatography (RP-C8). The recovery of substantially 100% pure mature IL-2 was about 60%. The IL-2 activity was found to be approximately 4 x 108 U/mg.
Table 3 Extraction of Mature IL-2 from E.coli membrane Total Total IL-2 Specific Protein Activity Activity Extraction (ma) (units) _ (u/mcr) 1M NaCl wash 0.5 0.3 x 106 0.6 x 105 1% Triton wash 3.3 5.5 x 106 1.7 x 106 1.75M guanidine-HC1 wash 2.5 10.0 x 106 4.0 x 106 7M guanidine-HC1 wash 10.1 779 x 106 77.1 x 106 (98%) 794.8 x 106 Example 4 The following example illustrates the purification of mature IL-2 from transformed E.coli paste utilizing a Procion Red Agarose chromatographic step in addition to HPLC.
Membrane Extraction of Cells Frozen E.coli cells (containing the plasmid for human IL-2) are thawed and 1 gm is added to 5 ml of Buffer A
(0.03 M Tris-HC1, pH 8.0, 0.005 M EDTA). After mixing 10 minutes, the cells are removed by centrifugation in a Sorval SS-34 rotor (10,000 rpm for 10 minutes). The superna-tant is removed and the cells resuspended in 5 ml Buffer A.
The suspended cells are broken with a Branson Cell Disruptor 350 (sonicator) (6 x 30 sec). The broken cells are centri-fuged (10,000 rpm for 10 minutes) and the supernatant con-taining the soluble proteins is discarded. The residue is washed once with 5 ml Buffer A and centrifuged (10,000 rpm for 10 minutes). The residue containing the membrane frac-Lion is suspended in Buffer B (1 M NaCl, 0.03 M Tris-HC1, pH
8.0, 0.005 M EDTA) with a Wheaton Dounce tissue homogenizes.
After mixing 10 minutes, the membrane fraction is removed by ._ 13~08~~
centrifugation in a Sorval SS-34 rotor (15,000 rpm for minutes). The residue is suspended in 5 ml Buffer C (1%
Triton X-100, 0.03 M Tris-HC1, pH 8.0), homogenized, mixed and centrifuged (15,000 rpm for 10 minutes). The centrifuged 5 residue is suspended in 5 ml of 1.75 M guanidine-HC1, homo-genized, mixed and centrifuged (15,000 rpm for 10 minutes).
The residue is washed once with 5 ml Buffer A and centrifu-ged. The membrane fracticn (residue) is extracted with 5 ml of 7 M guanidine-HC1. After centrifugation, the extract con-10 taming the IL-2 is saved and the residue is extracted a second time with 5 ml of 7 M guanidine-HC1. This extract is also Saved.
Chromatoaraphy on Procion Red Aq_arose The column is set up at room temperature and washed with two volumes of 7 M guanidine-HC1 before using the first time. The column is equilibrated with equilibration buffer (0.01 M Tris-HC1,'pH 7.9, 0.035 M NaCl) at 4°C. At least 1 ml of Procion red agarose should be used for each 100 y.g of IL-2 expected. The flow rate is 2 bed volumes per hour.
The 7 M guanidine-HC1 extract containing the IL-2 is diluted 40-fold with equilibration buffer and the precipitate remo-ved by centrifugation. The supernatant is then loaded on the column. The column is washed with two column volumes of equilibration buffer. The IL-2 is eluted in a peak after 1.5-2 volumes of elution buffer (0.01 M Tris-HC1, pH 7.9, 1.035 M NaCl). After the IL-2 has been removed, the column is rid of extraneous materials by washing with 6M guani-dine-HC1.
Chromatocrraphy on RP-P (C-18) The pH of the Procion red eluate is adjusted to 7 with a slow addition of 1.0 M acetic acid. Aliquots of 0.1 ml each are removed for assay purposed before and after pH adjust-ment. The neutralized eluate (60 mi) is pumped with 1 ml/min. onto a 0.31 x 25 cm RP-18 column, equilibrated with an equilibration buffer mixture consisting of 5% HPLC-13~.08~~
-Buffer II and 95% HPLC-Buffer I. Column flowthrough is collected and assayed for protein content and IL-2 bioacti-vity. The column is eluted at room temperature according to the gradient profile outlined in Table 4. The effluent is monitored at 220 nm and 1.5 ml fractions are collected and assayed for protein content and IL-2 activity. The peak of maximum IL-2 activity elutes at ca. 74% HPLC-Buffer II (59%
acteonitrile). Fractions are stored at 4 to 8°C and are pooled according to specific activity.
Table 4 Conditions for the chromatography of a typical Procion-red eluate on an RP-18 column Sample Load: 60 ml Column Dimensions 0.41 x 25 cm Flow Rate: 1 ml/min HPLC Buffer I: - 0.01 M phosphoric acid, 0.05 M
lithium chloride HPLC-Buffer II: 0.01 M phosphoric acid, 0.05 M
lithium chloride, 80% acetonitrile % HPLC-Buffer II Duration (min) Equilibration 5 20 Sample load - 60 Wash 5 15 Step 1, gradient 5 to 35 15 Step 2, gradient 35 to 85 50 Step 3, constant 85 5 Step 4, constant 5 5 All chromatographic steps are carried out at room tempe-rature.
Other groups have also reported the cloning and sequen-cing of the IL-2 gene. See Devos et al., ~~Molecular Cloning of Human Interleukin-2 cDNA and Its Expressior_ in E. coli~~, Nucleic Acids Research, 11, 4307-4323 (1983). See also Euro-pean patent application, publication No. 118 977.
Although these references describe the expression of IL-2 in transformed host cells, especially in E. coli, no purification procedures are disclosed which would permit one skilled in the art to obtain mature recombinant human IL-2 in a homogeneous or'substantially pure form.
The present invention relates to a process for the puri-fication of recombinant IL-2 especially of recombinant mature human IL-2. It provides a method for the purification of recombinant mature human IL-2 to homogeneity which over-comes the limitations of prior art purification methods.
This method comprises (a) cultivating a transformed organism containing a DNA
sequence which codes for mature human IL-2;
(b) causing a culture of the transformed organism of step (a) to express and accumulate mature human IL-2:
(c) lysing the culture of transformed organisms of step (b) to form a cell lysate mixture;
(d) separating the cell membrane components from the cell lysate mixture of step (c);
(e) ~,aasring the isolated cell membrane components with an extraction solution to yield a wash solution containing IL-2 ; and (f) chromatographically purifying the wash solution of step (e) to yield a substantially pure or homogenous recombinant human IL-2.
Brief Description of the Drawings Fig. 1 represents the DNA nucleotide sequence of pIL2-2B
and the corresponding amino acid sequence of mature human interleukin-2 (arrow represents amino terminus of mature IL-2 protein).
Fig. 2 graphically illustrates the construction of pRC2 from pBR322.
Fig. 3 graphically illustrates the construction of pRC23 containing a PL promoter.
Fig. 4 shows the construction of the structural gene for expression of Ser-IL-2.
Fig. 5 graphically illustrates the construction of a mature IL-2 expression vector without a promoter system (pRC
201/IL-2).
Fig. 6 graphically illustrates the construction of the mature IL-2 expression vector including a PL promoter system (pRC 233/IL2).
The procedure of the present invention relies on the surprising finding that the IL-2 protein expressed by a microbe tends to associate with the membrane fractions of the host microbe, principally the inner membrane of the microbe (the membrane being a lipid bi-layer often associa-ted with hydrophobic proteins). Therefore, separation of these membranes during the process of recovering IL-2 from the transformed microorganisms ensures high yield and purity levels of IL-2 at the end of the whole purification proce-dure.
While different known methods of cell lysis can be used in the process of the present invention, such as enzymatic or chemical lysis, lysis by sonification is the preferred method. The inner and outer cell membranes are then separa-ted from the other cellular components by known methods such as centrifugation.
Once the cell membranes are separated from the lysate mixture, they are washed with an extraction solution, pre-ferably salt and detergent solutions to yield a solution comprising at least about 50% IL-2. In a preferred embodi-ment, the cell membranes are washed in four separate steps with the salt and detergent solutions. The first step pre-ferably comprises washing the cell membranes with a salt solution, preferably 1M NaCl. In the second step the cell membrane fraction is washed with a detergent solution, pre-ferably 1% Triton X-100. In the third step the cell membrane fraction is washed with another salt solution, preferably 1.75M to 2M guanidine-HCl. The final wash is also with a salt solution, preferable about 4M to 7M guanidine-HC1. The wash solution which results from the fourth and final wash comprises at least about 50% IL-2.
The final IL-2 wash solution is then further purified by chromatography, preferably by reverse phase high performance liquid chromatography (HPLC). The HPLC step yields active IL-2 in a substantially 100% pure or homogeneous form. It is also forseeable that antibody affinity chromatography columns, utilizing polyclonal or monoclonal antibodies to IL-2, could be used as an alternative to HPLC. Other chroma-tographic procedures can also be utilized such as dye-affi-nity columns (e.g., Procion red agarose - as described in European Patent Application No. 83103582.9 published under No. 92163 on October 26, 1983) or sephacryl*5200 columns. In another preferred embodiment of this invention the chromatc-* trade mark.
_ 5 _ graphy comprises multiple steps, i.e. HPLC followed by a dye-affinity chromatography step.
In accordance with this invention the aforementioned purified IL-2 can be used for similar purposes as the other known immunomodulator compounds, e.g. as a means for trea-ting immunosuppressive conditions. It may be administered in pharmaceutically acceptable oral, injectable or topical com-position and modes. Dosage and dose rate may parallel that currently being used in clinical applications of known immunomodulator compounds, typically about 1-200 x106 units daily. These pharmaceutical compositions of the inven-tion contain said IL-2 in association with a compatible pharmaceutically acceptable carrier material. Any conventio-nal carrier material can be utilized. The carrier material can be an organic or inorganic inert carrier material sui-table for enteral, percutaneous or parenteral administra-tion. Suitable carriers include water, gelatin, gum arabic, lactose. starch, magnesium stearate, talc, vegetable oils, polyalkylene-glycols, especially polyethylene-glycols, petroleum jelly and the like. Furthermore, the pharmaceu-tical preparations may contain other pharmaceutically active agents. Additional additives such as flavoring agents, preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding.
The pharmaceutical preparations can be made up in any conventional form including: a) a solid form for oral administration such as tablets, capsules, pills, powders, granules, and the like; b) a liquid form for oral adminis-tration such as solutions, syrups, suspensions, elixirs and the like; c) preparations for parenteral administration such as sterile solutions, suspensions or emulsions; and d) pre-parations for topical administrations such as solutions, suspensions, ointments, creams, gels, micronized powders, aerosols and the like. The pharmaceutical preparations may be sterilized and/or may contain adjuvants such as preserva-tives, stabilizers, wetting agents, emulsifiers, salts for varying the osmotic pressure and/or buffers.
Parenteral dosage forms may be infusions or injectable solutions which can be injected intravenously or intramuscu-larly. The preparations can also contain other medicinally active substances. Additional additives such as preservati-ves, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of phar-l0 maceutical compounding.
The construction of IL-2 expression vectors and of transformants capable of expressing IL-2 is described in more detail below.
The amino acid sequence of the mature IL-2 protein is given in Figure 1. The~protein may be expressed in its mature form with a methionine at the amino terminus of the protein if the gene initiation codon is ATG. The methionine may or may not be removed by the host cell after expression.
The expression vectors used in this invention are deri-vatives of pBR322 containing the PL promoter isolated from bacteriophage lambda DNA. PL was the promoter of choice since it is a very strong promoter that can be efficiently and conveniently controlled by the lambda cI repressor, the gene for which may be located on the microorganism s chromo-some, a compatible vector or the same vector as that con-taining the PL promoter. The gene encoding the repressor carries a mutation, cIts, which renders tre repressor tempe-rature-sensitive. A vector which may be used with this invention and which contains the cI mutation is pRK248cIts, which is known in the art and is described by Kahn et al., P4ethods in Enzymology, 68, 268 (1979). At 30°C the repressor functions normally, and from about 37°C to about 42°C it is inactivated. Thus, the Pr promoter is repressed (turned--cff) at 30°C and derepressed (turned-on) at 42°C. The abi-1~~08~3 _ 7 _ ~, lity to control the PL promoter allows one to grow the culture at about 30°C to about 36°C without expressing the gene product and at an optimum time, shift the temperature from about 30°C to about 42°C to produce the desired mature human IL-2 product.
The preferred vector used in the present invention also contains an EcoRI restriction site distal (downstream in 3' direction) from the SD sequence. The following description serves to illustrate the preparation of a preferred vector, pRC23, into which the IL-2 gene is then introduced. However, other vectors may also be used.
In accordance with the procedure outlined in Figures 2 and 3 20 micrograms of pBR322 were digested with EcoRI and then used in two different reactions: 1) treatment with S1 nuclease to remove the 5' overhang, and 2) treatment with the Klenow fragment of DNA polymerase I to fill-in the ter-mini. Both reactions were terminated by phenol extraction followed by ethanol precipitation. DNA from each reaction was ligated to a synthetic BglII linker, digested with BglII
and PstI, and subjected to gel electrophoresis in 1% aga-rose. The 3600 by (base pairs) and 760 by fragments from both reactions were recovered from the gel. For the con-struction of pRC2, the 3600 by fragment from the Klenow reaction was ligated to the 760 by fragment from the S1 reaction. E. coli RR1 was transformed with the ligation mixture and transformants were selected on media containing 50 ug/ml ampicillin. Transformants containing the expected plasmid construction, i.e. a plasmid containing a BglII
restriction site in proximity of the EcoRl restriction site, were identified by restriction analysis of the isolated plasmid DNA. pRC23 was constructed by ligating synthetic oligonucleotides comprising a "consensus" or computer gene-rated ribosome-binding site (RBS), [Scherer et al. Nucleic Acids Research, 8, 3895 (1980)] to a 250 by Bgl II - Hae III
fragment containing the lambda. PL promoter, and inserting -a-~3~~~~3 the ligation product into pRC2.
In order to isolate the 250 by DNA fragment containing the lambda PL promoter, 1 microgram of a 450 by Bgl II -Hpa I DNA fragment (from by #35260 to 35710 of the lambda phage DNA sequence) was digested with Hae III and the pro-ducts were isolated by preparative gel electrophoresis in 5%
polyacrylamide. About 200 ng of the 250 by Bgl II - Hae III
fragment was ligated to 60 pmoles each of the synthetic oligonucleotides shown in Figure 3 which comprise most of the ~~consensus~~ RBS sequences generated by computer analysis as described by Scherer et al. The ligated molecules were digested with Bgl II and EcoRl (to eliminate oligomers) and purified by gel electrophoresis. The ligated products were then inserted into pRC2 which also had been digested with Bgl II and EcoRI. Transformation of E. coli strain RR1(pRK248cIts) was performed using standard methods and transformants were seclected on media containing ampicillin (50 ug/ml) at 30°C. 50 transformants were obtained, DNA
was isolated from 8 of those and analyzed by digesting with Hinc II. 6 of the 8 showed the expected restriction pattern and Maxam-Gilbert nucleotide sequence analysis of one of these confirmed the expected construction (designated pRC23).
Construction of a alasmidic expression vector containinu DN_A
coding for mature human IL-2 (1) Isolation of mRNA coding for human IL-2 mRNA was isolated from H33HJ-JAI cells (ATCC No.
CRL-8163, deposited August 26, 1982), a clone of Jurkat cell line FHCRC, after induction with PHA and PMA.
12,000 ml of H33HJ-JAI clone cell cultures (106 cells/ml) were grown in RPMI 1640 tissue culture medium supplemented with 10% Fetal Bovine Serum, 50 U/ml peni-cillin, 50 ug/ml streptomycin, 50 ug/ml gentamycin, and 300 ug/ml fresh L-glutamine. These cells were collected by centrifugation and resuspended in 6 1 of 13~0~~3 _ g _ the above detailed medium, lacking serum, but further supplemented with 1% PHA and 10 ng/ml PMA. Cells were dispended in 6 1 aliquots to sterile glass roller bottles and placed on a roller mill (10 rpm at 37°C).
Eight hours later, cells were collected by centrifuga-tion and mRNA was extracted using a standard phenol chloroform extraction procedure. Following phenol chloroform extraction, ethanol precipitated RNA was pelleted by high speed centrifugation, and resuspended in a 0.5M salt solution. Poly A-tailed mRNA contained in the total RNA population was collected by passage of this material over an oligo(dT)cellulose column. Ethanol precipitated mRNA was resuspended in water to a concen-tration of 500 ug/ml. 30 ng of RNA was then microin-jected into Xenopus oocytes. After 24 hours of incuba-tion in sterile Barth~s solution, 4 eggs were trans-ferred into a sterile 1.5 ml Eppendorf centrifuge tube and fed with 540-1500 microliters of fresh sterile Barth~s solution. 48 hours later, 200 microliters of egg conditioned medium was harvested and assayed for IL-Z
activity using a standard CTLL Cell 3H-Tdr incorpora-tion assay (Gillis et al., J. Immunoi. 120, 2027 [1978]). mRNA preparations which when translated by oocytes gave rise to significant IL-2 activity, were pooled, sized by standard sucrose density gradient centrifugation techniques and ethanol precipitated for cDNA library construction.
(2) cDNA Synthesis 3.5 ug of purified mRNA (approximately 10S on sucrose gradients) were used to synthesize double-stranded complementary DNA (ds cDNA) by the following method (Gubler and Hoffmann, Gene 25, 263-269 [1983]).
~3~-0853 (a) First strand cDNA synthesis:
The mRNA was suspended in 17.5 ml containing 50 mM
Tris-HC1, pH 8.3, 10 mM MgCl2, 10 mM DTT, 4 mM
Na-pyrophosphate, 1.25 mM dATP, 1.25 mM dGTP, 1.25 mM dTTP, 0.5 mM dCTP, 100 ug/ml of oligo(dT)12-18' and 10 Ci of 32P-dCTP (Amersham 3000 Ci/mMole). After incubation for 5 min. at 43°C, 3x00 units AMV reverse transcriptase/ml (Life Sciences, Inc.) was added and the mixture incubated for 30 min. at 43°C. The reaction was stopped by the addition of EDTA to 20 mM, extracted with phenol-cresol, and concentrated by ethanol precipi-tation. The yield of the first strand synthesis, as assayed by TCA-insoluble radioactivity, was calcu-lated to be 58.6 ng (1.7%).
(b) Second strand synthesis: , The cDNA-mRNA hybrid was resuspended in 5.8 micro-liters H20. To this solution, 7.7 microliters of the second strand synthesis mix was added to give a solution containing 20 mM Tris-HC1, pH 7.5, 5 mM
MgCl2, 10 mM (NH4)2504, 100 mM KC1, 0.15 nM
beta-NAD, 50 ug/ml BSA, 40 mM dNTPs, 8.5 units/ml of E. coli RNase H (Bethesda Research Labs), 230 Units/ml DNA polymerase I (Boehringer Mannheim), 10 units/ml E.coli DNA ligase (New England Biolabs).
The mixture was incubated for 60 min. at 12°C, then for 60 min. at 22°C. The reaction was stopped by addition of EDTA to 20 mM, and extracted with phenol-cresol. The cDNA was separated from free nucleotides by passage over a Sephadex G-50 fine column in 10 mM TEAB. The yield from this reaction was 107 ng of dscDNA (91%).
(~) Annealing and transformation 64 ng of dscDNA were tailed by addition of dGTP
using standard methods. The vector was prepared by digestion of pBR322 DNA with EcoRV (New England-Biolabs) and tailing with dCTP. 100 ng of tailed BR322 DNA and 1.25 ng of tailed cDNA inserts (ratio - 80:1) were annealed in 250 ul of O.O1M
Tris, pH 7.5, 1 mM EDTA, 0.15 M NaCl for 90 min. at 58°C, and transformed into competent E.coli RRI
cells. Transformed cells were plated on LB plates containing 100 ug/ml ampicillin (Bristol Labs), and incubated at 3?°C for 12 hours. A total of 3,200 colonies were generated for the IL-2 cDNA
library.
(3) Screenincr of cDNA library for.IL-2 gene seauences To detect full-length cDNA copies of the IL-2 gene, a synthetic deoxy-oligonucleotide probe was used which corresponds to nucleotides 45-65 of the human IL-2 cDNA
sequence published by Taniguchi~ et al. (Nature 302, 305-310 [1983]). This probe [ACAATGTACAGGATGCAACTC] was synthesized by the solid-phase phosphodiester method, purified by HPLC, and labeled by using 32P-ATP (ICN
Pharmaceuticals, 7000 Ci/mM) and polynucleotide kinase (New England Biolabs). Colonies representing the cDNA
library were transferred to nitrocellulose filters by the method of Grunstein and Hogness (Methods in Enzymo-logy 68, 379 [1979]). After hybridization at 30°C for 16 hours, filteres were washed in 4xSSC at 45°C for 45 minutes, dried, and autoradiographed. A single posi-tive colony was detected and found to contain the entire IL-2 coding sequence. This colony, designated pIL2-2B, was used to prepare DNA for nucleotide sequence analysis and for expression in E.coli. Nucleotide sequence analy-sis showed it to be identical to that of the sequence published by Taniguchi et al. with two differences:
pIL2-2B contains an insert which begins at nucleotide 17, as designated in the Taniguchi sequence, and has a substation of a G at position 503.
.. ~~~OS~3 (4) Construction of the E.coli plasmidic vector containin DNA coding for Ser-IL-2.
An E.coli expression vector for IL-2 was constructed from three segments (see Fig. 4): (1) the vector pRC23, with the lambda PL promoter, (2) a synthetic adapter molecule, and (3) a Hgi AI - Aha III fragment isolated from the IL-2 cDNA. The vector DNA was prepared by digestion of 50 ng of pRC23 DNA with EcoRI and EcoRV, followed by phenol extraction and ethanol precipitation.
l0 The synthetic adagter molecule was obtained by annealing two complementary synthetic deoxy-oligonucleotide sequences, A and B:
(A) 5' AATTCAATTATGAGTGCA 3' (B) 3' GTTAATACTC 5' This double-stranded adapter can anneal to an EcoRI site at its 5' end and to a HgiAI site at its 3' end. The cDNA insert was prepared by digestion of pIL2-2B DNA
with the restriction enzyme BamHl (Bethesda Research Labs), which releases the 1 kilobase IL-2 insert from this clone. The BamHl fragment was gel-purified and further digested with HgiAI (New England Biolabs) and Aha III (New England Biolabs), then phenol-extracted and ethanol precipitated. HgiAI cuts between the alanine and proline codons at the beginning of the sequence coding for mature IL-2. The cloning strategy for expression uses the EcoRI site adjacent to the PL promoter in the pRC23 vector. The synthetic adapter molecule can join this EcoRI site in the vector to the HgiAI site at the start of the cDNA IL-2 sequence. The adapter was desig-ned to create the methionine codon for translation ini-tation. Codons for serine and for alanine, the first amino acid of mature IL-2, are created when the adapter and the cDNA are ligated at the HgiAI site. The cDNA is joined to pRC23 via blunt-end ligation of the AhaIII
site to the EcoRV site in the vector DNA.
M
- i3 -Ligation of the three segments was performed in a volume of 10 y.l which contained 0.05 pM each of the vector, synthetic adapter and cDNA insert DNAs, 65 mM Tris, pH
7.6, 10 mM MgCl2, 0.5 mM ATP, and 15 mM beta-mercapto-ethanol. The ligation mixture was heated at 65°C for 5 minutes, cooled to 4°C before addition of 200 Units of T4 DNA ligase (New England Biolabs), then incubated at 4°C for 16 hours. The T4 DNA ligase was inactivated by heating at 65°C for 5 minutes. Then the ligated DNAs were digested with EcoRV to remove any undigested vector DNA. The mixture was then used for transformation of E.coli strain RRI (pRK248cIts), and these cells were grown at 30°C for 15 hcurs.
The colonies were transferred to nitrocellulose filters as described previously, baked, and hybridized with a radioactive probe of 32P-labeled synthetic adapter molecule A. One positive colony, designated pRC23/IL-2, #4-1, was chosen for analysis. This clone was found to synthesize more than 200,000 units/ml of IL-2 when the PL promoter was induced to express at 42°C. The IL-2 activity was detected by bioassay on CTLL cells, an indicator cell line for IL-2 (as described in Gillis et al. J. Immunol. 120, 2027 [1978]).
(5) Construction of an E.coli ex ression vector for urodu-cing mature IL-2 (with alanine as the first amino acid at the amino terminus) To express mature IL-2 in E.coli, the following strategy (illustrated in Fig. 5) was followed. A HgiAI restric-tion endonuclease site is located at the Ser-Ala junc-tion, the cleavage site for the removal of the signal peptide of IL-2 (Robb et al., PNAS, 80, 5990-5994 [1983]). Following digestion with HgiAI, the termini were made blunt-ended by treating with T4 DNA poly-merase. The resulting molecules were then blunt-end ligated to a 108 by BglII-Hae III fragment isolated from phage lambda DNA, digested with BglII and XbaI and inserted between BglII and RbaI sites in the vector pRC23/IL-2, #4-1. This intermediate cloning step was included to ensure that the T4 DNA polymerase treatment occurred as expected, which was confirmed by the crea-tion of a new StuI site from the joining of the HaeIII
terminus to the blunt-ended HgIAI terminus. Redigesting with StuI conveniently regenerates at this site the blunt end beginning with the CCT proline codon. The intermediate plasmid construction was designated pRC201/I1-2. Two synthetic deoxyoligonucleotides were designed which incorporate an ATG-translational initia-tion codon, restore the alanine codon, and create an EcoRI terminus. These oligomers were ligated to the EcoRI terminus of the expression vector pRC23, digested with PstI, and the resulting 1025 by fragment was gel purified. The 1025 by (PstI to blunt-end) fragment was inserted between the PstI site and the newly created StuI site in pRC201/IL-2. Transformants containing the expected construction were identified by restriction analysis of the isolated plasmid DNA. The confirmed plasmid construction was designated pRC233/I1-2 (see Fig. 6).
Preferred host organisms for transformation by a vector containing the gene for IL-2 in connection with the present invention include bacteria such as strains of E.coli; bacillaceae, such as Bacillus substillis and the like. Yeasts form a further preferred group of microorganisms for transformation.
A specifically preferred microorganism employed as the recipient in the transformation procedures is Esche-richia coli K-12 strain 294 as described in British patent Publication No. 2055382A, deposited with the American Type Culture Collection, ATCC Accession No.
31446, on October 28, 1978. However, also other known 13~.0~~3 E.coli strains such as E.coli RR1, ATCC Accession No.
31343, or other microorganisms many of which are deposi-ted and available from recognized microorganism deposi-tory institutions, such as the American Type Culture Collection can be used as host organisms. In the prac-tice of this invention overnight cultures of the trans-formed E.coli are grown in LB broth at 30°C. One liter of the overnight culture is preferably diluted to 10 liters with minimal M-9 medium containing casamino acids. At logarithmic growth, the culture is shifted from 30°C to 42°C to induce IL-2 production. Following incubation at 42°C for 2-3 hours, the bacteria are harvested by centrifugation. All fermentations and procedures were performed in accordance with recombinant DNA guidelines of the National Institutes of Health. The purification steps are described in detail in the follo- -wing Examples.
Example 1 One gram of IL-2 (having serine at the NH2 terminus) producing transformed E.coli cells were suspended in 30 mM
Tris-HC1, pH 8.0, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride and lysed by sonification. The lysis mixture was centrifuged at 14,000 x g for 15 minutes. The membrane portion of the centrifuged lysate was then removed and iso-lated from the other components of the lysate. The membrane component was then subjected to the four washing or IL-2 extraction steps shown below in Table 1. Each wash solution was used in an amount of at least 5 ml/gram of cells. The bulk of the IL-2 activity was extracted in the final wash as detailed in Table 1. The final resultant wash solution which contained the bulk of the IL-2 activity and which was at least about 50% pure as judged by SDS-PAGE, was then subjec-ted to reverse phase HPLC (RP-C8). There was a 40-60% reco-very of substantially 100% pure IL-2 (with serine at the NH2 terminus). The IL-2 activity was found to be at least <",, , *Trademark -16 - ~3~0~~~
1 x loa u/mg.
Table 1 Extraction of IL-2 from E.coli membrans Total Total IL-2 Specific Protein Activity Activity Extraction (mcr) units u/m 1M NaCl wash 0.4 mg 0.03 x 106 0.1 x 106 1% Triton wash 2 mg 0.75 x 106 0.4 x 106 1.75 guanidine-HC1 wash 1 mg 1.5 x 106 1.5 x 106 7M guanidine-HC1 wash 4.7 mg 250 x 106 53 x 106 (99%) 252.3 x 106 Example 2 This example serves to demonstrate that IL-2 tends to become associated with the membrane components of the trans-formed E.coli host cells.
In order to demonstrate this, one gram of serine-NH2 terminus IL-2 producing transformed E.coli cells were sus-pended in 10 ml of 20% sucrose, 30 mM Tris-HC1, pH 8.0, and lysed using lysozyme-EDTA to separate proteins which are localiced in the periplasmic space. The remainder of the lysed mixture was then subjected to sonification. The mem-brane portion (inner and outer membranes) was then separated from the other cellular components by sucrose gradient cen-trifugation with which the inner and outer membranes were also separated. Table 2 shows that the majority of IL-2 activity was located in the inner cellular membrane.
_ 17 - ~3~O8~J
Table 2 Localization of IL-2 in E.coli cells Total Total IL-2 Recovery of Protein Activity IL-2 Fraction (mct) (units) [%~
Soluble Fraction 37 mg 2 x 106 0.3 Periplasmic Fraction 2 mg 10 x 106 1.5 Outer Membrane 6 mg 8 x 106 1.2 Inner Membrane 15 mg 6.6 x 108 97 Example 3 One gram of mature IL-2 producing transformed E.coli cells was suspended in 30 mM Tris-HC1, pH 8, 5 mM EDTA, 1 mM
phenylmethylsulfonyl'fluoride and lysed by sonification. The lysis mixture was centrifuged at to 14,000 x g for 15 minu-tes. The membrane portion of the centrifuged lysate was iso-lated from the other components of the lysate. The membrane portion was then subjected to the four washing or IL-2 extraction steps shown below in Table 3. Each wash solution was used in an amount of at least 5 ml per each gram of cells. The bulk of the IL-2 activity was finally extracted in the final wash as detailed in Table 3. The final resul-tant wash solution which contained the bulk of the IL-2 activity and which was at least 50% pure as judged by SDS--PAGE, was then subjected to reverse phase high performance liquid chromatography (RP-C8). The recovery of substantially 100% pure mature IL-2 was about 60%. The IL-2 activity was found to be approximately 4 x 108 U/mg.
Table 3 Extraction of Mature IL-2 from E.coli membrane Total Total IL-2 Specific Protein Activity Activity Extraction (ma) (units) _ (u/mcr) 1M NaCl wash 0.5 0.3 x 106 0.6 x 105 1% Triton wash 3.3 5.5 x 106 1.7 x 106 1.75M guanidine-HC1 wash 2.5 10.0 x 106 4.0 x 106 7M guanidine-HC1 wash 10.1 779 x 106 77.1 x 106 (98%) 794.8 x 106 Example 4 The following example illustrates the purification of mature IL-2 from transformed E.coli paste utilizing a Procion Red Agarose chromatographic step in addition to HPLC.
Membrane Extraction of Cells Frozen E.coli cells (containing the plasmid for human IL-2) are thawed and 1 gm is added to 5 ml of Buffer A
(0.03 M Tris-HC1, pH 8.0, 0.005 M EDTA). After mixing 10 minutes, the cells are removed by centrifugation in a Sorval SS-34 rotor (10,000 rpm for 10 minutes). The superna-tant is removed and the cells resuspended in 5 ml Buffer A.
The suspended cells are broken with a Branson Cell Disruptor 350 (sonicator) (6 x 30 sec). The broken cells are centri-fuged (10,000 rpm for 10 minutes) and the supernatant con-taining the soluble proteins is discarded. The residue is washed once with 5 ml Buffer A and centrifuged (10,000 rpm for 10 minutes). The residue containing the membrane frac-Lion is suspended in Buffer B (1 M NaCl, 0.03 M Tris-HC1, pH
8.0, 0.005 M EDTA) with a Wheaton Dounce tissue homogenizes.
After mixing 10 minutes, the membrane fraction is removed by ._ 13~08~~
centrifugation in a Sorval SS-34 rotor (15,000 rpm for minutes). The residue is suspended in 5 ml Buffer C (1%
Triton X-100, 0.03 M Tris-HC1, pH 8.0), homogenized, mixed and centrifuged (15,000 rpm for 10 minutes). The centrifuged 5 residue is suspended in 5 ml of 1.75 M guanidine-HC1, homo-genized, mixed and centrifuged (15,000 rpm for 10 minutes).
The residue is washed once with 5 ml Buffer A and centrifu-ged. The membrane fracticn (residue) is extracted with 5 ml of 7 M guanidine-HC1. After centrifugation, the extract con-10 taming the IL-2 is saved and the residue is extracted a second time with 5 ml of 7 M guanidine-HC1. This extract is also Saved.
Chromatoaraphy on Procion Red Aq_arose The column is set up at room temperature and washed with two volumes of 7 M guanidine-HC1 before using the first time. The column is equilibrated with equilibration buffer (0.01 M Tris-HC1,'pH 7.9, 0.035 M NaCl) at 4°C. At least 1 ml of Procion red agarose should be used for each 100 y.g of IL-2 expected. The flow rate is 2 bed volumes per hour.
The 7 M guanidine-HC1 extract containing the IL-2 is diluted 40-fold with equilibration buffer and the precipitate remo-ved by centrifugation. The supernatant is then loaded on the column. The column is washed with two column volumes of equilibration buffer. The IL-2 is eluted in a peak after 1.5-2 volumes of elution buffer (0.01 M Tris-HC1, pH 7.9, 1.035 M NaCl). After the IL-2 has been removed, the column is rid of extraneous materials by washing with 6M guani-dine-HC1.
Chromatocrraphy on RP-P (C-18) The pH of the Procion red eluate is adjusted to 7 with a slow addition of 1.0 M acetic acid. Aliquots of 0.1 ml each are removed for assay purposed before and after pH adjust-ment. The neutralized eluate (60 mi) is pumped with 1 ml/min. onto a 0.31 x 25 cm RP-18 column, equilibrated with an equilibration buffer mixture consisting of 5% HPLC-13~.08~~
-Buffer II and 95% HPLC-Buffer I. Column flowthrough is collected and assayed for protein content and IL-2 bioacti-vity. The column is eluted at room temperature according to the gradient profile outlined in Table 4. The effluent is monitored at 220 nm and 1.5 ml fractions are collected and assayed for protein content and IL-2 activity. The peak of maximum IL-2 activity elutes at ca. 74% HPLC-Buffer II (59%
acteonitrile). Fractions are stored at 4 to 8°C and are pooled according to specific activity.
Table 4 Conditions for the chromatography of a typical Procion-red eluate on an RP-18 column Sample Load: 60 ml Column Dimensions 0.41 x 25 cm Flow Rate: 1 ml/min HPLC Buffer I: - 0.01 M phosphoric acid, 0.05 M
lithium chloride HPLC-Buffer II: 0.01 M phosphoric acid, 0.05 M
lithium chloride, 80% acetonitrile % HPLC-Buffer II Duration (min) Equilibration 5 20 Sample load - 60 Wash 5 15 Step 1, gradient 5 to 35 15 Step 2, gradient 35 to 85 50 Step 3, constant 85 5 Step 4, constant 5 5 All chromatographic steps are carried out at room tempe-rature.
Claims (13)
1. A method for producing substantially homogeneous mature recombinant human interleukin-2 (IL-2), which comprises (a) cultivating a transformed microorganism containing a DNA sequence which codes for mature human IL-2;
(b) causing a culture of the transformed microorganism of step (a) to express and accumulate mature human IL-2;
(c) lysing the culture of transformed microorganism of step (b) to form a cell lysate mixture;
(d) separating the cell membrane components from the cell lysate mixture of step (c):
(e) washing the isolated cell membrane components with an extraction solution, comprising salt and detergent to yield a wash solution containing IL-2.
(f) chromatographically purifying the wash solution of step (e) to yield a substantially pure or homogeneous recombinant human IL-2.
(b) causing a culture of the transformed microorganism of step (a) to express and accumulate mature human IL-2;
(c) lysing the culture of transformed microorganism of step (b) to form a cell lysate mixture;
(d) separating the cell membrane components from the cell lysate mixture of step (c):
(e) washing the isolated cell membrane components with an extraction solution, comprising salt and detergent to yield a wash solution containing IL-2.
(f) chromatographically purifying the wash solution of step (e) to yield a substantially pure or homogeneous recombinant human IL-2.
2. The method of claim 1 wherein the culture of transformed microorganisms are lysed by sonification.
3. The method of claim 1 wherein the cell membrane components are separated from the cell lysate mixture by centrifugation.
4. The method of claim 1 wherein the isolated cell membrane components are washed with salt and detergent solutions prior to washing with the extraction solution.
5. The method of claim 4 wherein the salt and detergent washes are carried out sequentially in three separate steps.
6. The method of claim 5 wherein the cell membrane components are washed in the first step with a NaCl solution, in the second step with a detergent and in the third step with a guanidine-HCl solution having a molarity of about 1.75 to 2Ø
7. The method of claim 6 wherein the concentration of the guanidine-HCl solution is about 7M.
8. The method of claim 1 wherein the chromatographic purification is carried out by high performance liquid chromatography.
9. The method of claim 1 wherein the chromatographic purification is carried out by affinity chromatography.
10. The method of claim 9 wherein the affinity chromatography is dye affinity chromatography.
11. The method of claim 1 wherein the chromatographic purification is a multiple step procedure utilizing high performance liquid chromatography and affinity chromatography.
12. The method of claim 2 wherein the cell membrane components are separated from the cell lysate mixture by centrifugation.
13. The method of claim 2, 3 or 12 wherein the isolated cell membrane components are washed with salt and detergent solutions prior to washing with the extraction solution.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56498683A | 1983-12-23 | 1983-12-23 | |
US564,986 | 1983-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1340853C true CA1340853C (en) | 1999-12-21 |
Family
ID=24256731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000470498A Expired - Lifetime CA1340853C (en) | 1983-12-23 | 1984-12-19 | Purification of recombinant interleukin-2 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0147819B1 (en) |
JP (2) | JPH0728753B2 (en) |
AT (1) | ATE76905T1 (en) |
AU (1) | AU580276B2 (en) |
CA (1) | CA1340853C (en) |
DE (1) | DE3485759D1 (en) |
DK (1) | DK174501B1 (en) |
IE (1) | IE57914B1 (en) |
IL (1) | IL73882A (en) |
NZ (1) | NZ210634A (en) |
PH (1) | PH19584A (en) |
ZA (1) | ZA849910B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10889643B2 (en) | 2016-01-11 | 2021-01-12 | Universität Zürich | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
US10894828B2 (en) | 2014-07-10 | 2021-01-19 | Universität Zürich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925919A (en) * | 1984-04-25 | 1990-05-15 | Roland Mertelsmann | Purified interleukin 2 |
US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
JPS60115528A (en) * | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | Human interleukin-2 protein, its production and pharmacological composition containing the same |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
US4908434A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Process for preparing purified interleukin-2 |
WO1986002068A1 (en) * | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
IL76360A0 (en) * | 1984-09-26 | 1986-01-31 | Takeda Chemical Industries Ltd | Mutual separation of proteins |
EP0226639B1 (en) * | 1985-05-29 | 1990-11-14 | The Green Cross Corporation | Process for preparing heterogenic protein |
US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
DE3581412D1 (en) * | 1985-07-16 | 1991-02-21 | Green Cross Corp | METHOD FOR PRODUCING HETEROPROTEINS. |
US5831022A (en) * | 1986-02-18 | 1998-11-03 | Hoffmann-La Roche Inc. | Purification of recombinant human IL-1α |
CA1339757C (en) * | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
US5162507A (en) * | 1987-05-11 | 1992-11-10 | Cetus Corporation | Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms |
US5162503A (en) * | 1987-05-19 | 1992-11-10 | Hoffmann-La Roche, Inc. | Purification of interleukin-2 by receptor-affinity chromatography |
EP0337243A1 (en) * | 1988-04-14 | 1989-10-18 | F. Hoffmann-La Roche Ag | Process for purifying recombinant human interleukin-2 |
ZA898139B (en) * | 1988-11-17 | 1990-08-29 | Hoffmann La Roche | Recombinant interleukin-2 hybrid proteins |
IT1262981B (en) * | 1992-09-09 | 1996-07-23 | Tecnogen Scpa | PROCEDURE FOR PURIFYING THE BIG ENDOTELINE PROTEIN |
US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
JP2006141263A (en) * | 2004-11-18 | 2006-06-08 | Kyoto Univ | Method for producing (R) -hydroxynitrile lyase |
RU2565553C2 (en) * | 2013-04-09 | 2015-10-20 | Общество с ограниченной ответственностью "Стратегия" | Method of obtaining interleukin-2 preparation, interleukin-2 preparation and pharmaceutical immunomodulating preparation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58159420A (en) * | 1982-03-18 | 1983-09-21 | Ajinomoto Co Inc | Purification method of interleukin 2 |
EP0091539B2 (en) * | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells |
ATE37564T1 (en) * | 1982-04-20 | 1988-10-15 | Sloan Kettering Inst Cancer | PURIFICATION OF INTERLEUKIN-2. |
JPS58198293A (en) * | 1982-05-12 | 1983-11-18 | Shionogi & Co Ltd | Production of immunoregulator such as interleukin |
JPS59144719A (en) * | 1983-02-03 | 1984-08-18 | Japan Found Cancer | Gene coding interleukin-2 polypeptide, recombined dna substance containing gene, and preparation of interleukin-2 using live cell strain containing dna substance and cell |
ZA842025B (en) * | 1983-03-21 | 1984-11-28 | Hoffmann La Roche | Interleuken-2 |
JPS60115528A (en) * | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | Human interleukin-2 protein, its production and pharmacological composition containing the same |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
DE3419995A1 (en) * | 1984-05-29 | 1985-12-05 | Hoechst Ag, 6230 Frankfurt | GENE TECHNOLOGICAL METHOD FOR PRODUCING HUMAN INTERLEUKIN-2 AND MEANS FOR CARRYING OUT THIS METHOD |
-
1984
- 1984-12-19 DK DK198406124A patent/DK174501B1/en not_active IP Right Cessation
- 1984-12-19 ZA ZA849910A patent/ZA849910B/en unknown
- 1984-12-19 CA CA000470498A patent/CA1340853C/en not_active Expired - Lifetime
- 1984-12-19 NZ NZ210634A patent/NZ210634A/en unknown
- 1984-12-20 IL IL73882A patent/IL73882A/en not_active IP Right Cessation
- 1984-12-20 AU AU36995/84A patent/AU580276B2/en not_active Expired
- 1984-12-21 AT AT84116054T patent/ATE76905T1/en not_active IP Right Cessation
- 1984-12-21 IE IE3320/84A patent/IE57914B1/en not_active IP Right Cessation
- 1984-12-21 EP EP84116054A patent/EP0147819B1/en not_active Expired - Lifetime
- 1984-12-21 DE DE8484116054T patent/DE3485759D1/en not_active Expired - Lifetime
- 1984-12-22 JP JP59271681A patent/JPH0728753B2/en not_active Expired - Lifetime
- 1984-12-26 PH PH31644A patent/PH19584A/en unknown
-
1994
- 1994-09-08 JP JP6215128A patent/JP2864996B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10894828B2 (en) | 2014-07-10 | 2021-01-19 | Universität Zürich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
US10889643B2 (en) | 2016-01-11 | 2021-01-12 | Universität Zürich | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
US11851484B2 (en) | 2016-01-11 | 2023-12-26 | Universität Zürich | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
Also Published As
Publication number | Publication date |
---|---|
IL73882A (en) | 1989-05-15 |
IE843320L (en) | 1985-06-23 |
AU580276B2 (en) | 1989-01-12 |
JPS60172295A (en) | 1985-09-05 |
JPH07233082A (en) | 1995-09-05 |
EP0147819A2 (en) | 1985-07-10 |
NZ210634A (en) | 1989-05-29 |
JPH0728753B2 (en) | 1995-04-05 |
PH19584A (en) | 1986-05-26 |
EP0147819B1 (en) | 1992-06-03 |
DK612484A (en) | 1985-06-24 |
EP0147819A3 (en) | 1987-09-23 |
JP2864996B2 (en) | 1999-03-08 |
DK612484D0 (en) | 1984-12-19 |
DK174501B1 (en) | 2003-04-28 |
DE3485759D1 (en) | 1992-07-09 |
ZA849910B (en) | 1985-09-25 |
IE57914B1 (en) | 1993-05-19 |
IL73882A0 (en) | 1985-03-31 |
ATE76905T1 (en) | 1992-06-15 |
AU3699584A (en) | 1985-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1340853C (en) | Purification of recombinant interleukin-2 | |
US5643758A (en) | Production and purification of a protein fused to a binding protein | |
US4762791A (en) | Human immune interferon | |
US4456748A (en) | Hybrid human leukocyte interferons | |
US5460811A (en) | Mature human fibroblast interferon | |
US7635466B1 (en) | DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon-like polypeptides | |
US5096705A (en) | Human immune interferon | |
US4897348A (en) | Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof | |
EP0158198A1 (en) | DNA and use thereof | |
CA1340173C (en) | Production and purification of a protein fused to a binding protein | |
US6268180B1 (en) | Recombinant human recombinant human interleukin-1α | |
US5582824A (en) | Recombinant DES-CYS-TYR-CYS human immune interferon | |
EP0089676A2 (en) | Novel DNA and use thereof | |
JPH0240080B2 (en) | ||
EP0091527A2 (en) | DNA sequences, recombinant DNA molecules and processes for producing human serum albumin-like polypeptides | |
US4801685A (en) | Microbial production of mature human leukocyte interferon K and L | |
US5026639A (en) | Method to improve mRNA translation and use thereof for production of platelet factor-4 | |
EP0126230A1 (en) | Novel DNA and use thereof | |
JPS61149089A (en) | DNA base sequence, polypeptide secretion expression vector, and transformed microorganism | |
WO1985001067A1 (en) | Recombinant materials and methods for producing human connective tissue-activating peptide-iii and analogs thereof | |
CN85103306A (en) | Purification of Recombinant Human Interleukin-2 | |
JPH08245695A (en) | Substance having antitumor activity | |
JPS61181380A (en) | Novel dna and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |
Effective date: 20161221 |